Form 4 for PTGX Protagonist Therapeutics, Inc

Accepted 2023-06-02 00:00:00 ET · period of report 2023-05-31 · accession 0001104659-23-067689 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2023-06-02	2023-05-31	PTGX	Ali Asif	CFO	A - Grant	$0.00	+12.0K	35.2K	+52%	$0
	2023-06-02	2023-05-31	PTGX	Ali Asif	CFO	F - Tax	$26.07	-4,150	31.0K	-12%	-$108.2K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-05-31	A	A	12,000	$0.00	35,186	D	—	—	(F1) Represents settlement by the Issuer of performance stock units ("PSUs") granted to the Reporting Person under the Company's 2016 Equity Incentive Plan on May 31, 2022, which vested based on the Issuer's achievement of corporate performance objectives. (F2) The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the "Lock-up Date") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date.
2	Common	Common Stock	2023-05-31	F	D	4,150	$26.07	31,036	D	—	—	(F3) Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of PSUs. (F2) The shares of common stock reported on this Form 4 are subject to a lock-up agreement between the reporting person and J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler & Co., dated April 4, 2023 (the "Lock-up Date") pursuant to which the shares of common stock reported herein cannot be sold for 60 days following the Lock-up Date.